DMYD-B:STO
Diamyd Medical AB
SEK 1.01
arrow_downward
-0.39%(-0.0040) 1D
Oct 20, 5:29:52 PM GMT+2 · SEK
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DMYD-B...
Open
SEK 1.02
High
SEK 1.03
Low
SEK 1.00
Mkt. cap
153.60M
Avg. vol.
842.57K
Volume
124.16K
52-wk high
SEK 17.88
52-wk low
SEK 0.90
EPS
-SEK 1.76
Shares outstanding
134.00M
No. of employees
42
Open
SEK 1.02
High
SEK 1.03
Low
SEK 1.00
Mkt. cap
153.60M
Avg. vol.
842.57K
Volume
124.16K
52-wk high
SEK 17.88
52-wk low
SEK 0.90
EPS
-SEK 1.76
Shares outstanding
134.00M
No. of employees
42
News stories
From web sources and news partners
ChartMill
·
43 minutes ago
Most Active S&P 500 Stocks in Today's Session
Yahoo Finance
·
1 hour ago
Ciena (CIEN): Is the AI-Optical Boom Enough to Carry It Into the S&P 500?
TradingView
·
1 hour ago
S&P 500 Could Hit 8,300 By May 2027, Says Morgan Stanley Investment Chief Predicting ‘Final Innings’ Of Stock Market Correction
Insider Monkey
·
1 hour ago
Alnylam (ALNY): Can the RNAi Franchise Get it an Entry into the S&P 500 Index?
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB